Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU ‘Ready To Approve’ COVID-19 Vaccine On 23 December

Commission Negotiating Vaccine Contract Disclosure With Companies

Executive Summary

European parliamentarians have defended the formal marketing authorization approach being taken by the EU, saying “safety is of the utmost importance” if there is to be trust in coronavirus vaccines.

You may also be interested in...



Pfizer/BioNTech COVID-19 Vaccine Wins EU Approval

The first COVID-19 vaccine will shortly be available to the EU member states, after the European Commission today approved Pfizer/BioNTech's BNT162b2 just hours after the European Medicines Agency issued a positive opinion on the product. The EMA says that uncertainties remain over the ability of the vaccine to prevent transmission of the coronavirus and whether the new variant strain will render this and other vaccines less effective. 

EMA Brings Forward Moderna Vaccine Decision Date

This week has seen two key decisions by the European Medicines Agency designed to speed up the availability of COVID-19 vaccines in the EU.

Hurry Up And Approve: EMA Brings Vaccine Decision Forward After Political Pressure

Resurgence of the coronavirus across Europe made the approval of Pfizer/BioNTech vaccine and the start of immunization programs more urgent.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel